Other oncology experience

  • Scenario model and value messages for oncology in Australia, France, Austria, Switzerland, Belgium, Germany, Italy, Slovenia and the Netherlands
  • Scenario model and policy messages in oncology (Health Impact Projection) for Korea, Norway and Germany
  • Development of a slide deck on the Health Impact Projection in oncology for presentation at a conference
  • Development of an evidence evaluation framework in cancer
  • Creative values demonstration in oncology
  • Budget impact model and clinical data update for the Health Impact Projection in oncology
  • Training on a UK budget impact model for a chemotherapy drug
  • External communications for a multi-indication value-based pricing model in oncology
  • Value based pricing model manuscript in oncology
  • Adaptation of a value-based pricing multi-indication global model in oncology to Belgium and the US
  • Cost utility model and pilot version of the Safety Profile Model for oncology
  • Economic model for an erythropoietin treatment in cancer
  • Extension and creation of economic evidence on an erythropoietin treatment in cancer
  • Burden of disease deck on biomarkers in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced (stage IV) cancerous tumours
  • Payer value deck on biomarkers in MSI-H or dMMR advanced (stage IV) cancerous tumours
  • Response to payer questions on biomarkers in MSI-H or dMMR advanced (stage IV) cancerous tumours
  • Response to payer questions update on biomarker response in various cancer indications
  • Support for the commercialisation of treatment for an immune-response modifier in oncology
  • Competitor intelligence tracking in oncology
  • Implementation guide in all indications of oncology
  • Frequently asked questions deck in oncology biomarkers and companion diagnostics
  • EU market access training in oncology
  • Steering committee meeting in oncology
  • Face-to-face meeting with external experts for review and validation of scenario policy model in oncology
  • Country-level advisory board for a health impact model in oncology
  • Country specific advisory board for the Health Impact Projection model for the Netherlands
  • One-day workshop on Health Impact Projection in oncology
  • Slovenia-focused advisory board on the Health Impact Projection tool in oncology
  • Literature and reimbursement review of IV versus SC oncology therapies, and development of a conference poster
  • Systematic literature review on oncology drugs that have made the switch from IV to SC formulation
  • Literature review and consultancy on oncology
  • Budget impact model on an oncology biosimilar
  • Budget impact model for a biosimilar in multiple oncology indications
  • Health Economics and Outcomes Research (HEOR) training academy in oncology
  • Development of an abstract to communicate a systematic literature review in oncology
  • Development of a poster on IV and SC therapies in immuno-oncology
  • Health Impact Projection expert meeting on oncology
  • Development of a poster on a systematic review of real-world outcomes of IV and SC therapies in oncology
  • Value-based pricing model in oncology for Belgium
  • Reimbursement scenario analysis for a Korean Health Impact Projection model in oncology
  • Multi-indication budget impact and resource utilisation model in oncology
  • Access landscape analysis for remote care coordination in oral oncotherapy
  • Multi-indication cost-effectiveness model in oncology for Korea
  • HE support for launch of a new immunotherapy dose in oncology
  • Manuscript on a multi-indication cost-effectiveness model in oncology for Korea
  • Value evidence compendium in pan-tumour oncology
  • Development of a Health Impact Projection model in oncology for Korea, Turkey, Australia and other countries in Europe and Globally
  • Adaptations of a Health Impact Projection model to Japan, Turkey, Portugal, Australia, New Zealand and Hong Kong
  • PRO consulting for regulatory affairs and investigator training slides in malignant ascites
  • PRO endpoint consulting in oncology
  • Clinical investigator PROs for chemotherapy trials
  • Comprehensive PRO strategy in oncology
  • Support in the development of a PRO strategy for four compounds in 6-8 oncology indications
  • PRO booklet review and edits adaptation on cancer
  • Selection and implementation of PROs such as health-related quality of life and symptoms assessment in the clinical development of new compounds in the field of oncology
  • Consultancy in administration of PROs in a clinical oncology trial
  • Statistical review of PRO aspects of an oncology protocol
  • EMEA training on PROs in haematology and oncology
  • Identification of PRO measures suitable for implementation in phase III oncology and immunotherapy trials
  • Strategic consulting on PRO endpoints for FDA approvable claims
  • Development of a PRO best practices document – interactions with international regulatory and HTA agencies in oncology
  • PRO oncology workshop
  • Development of a PRO dossier for the Cancer Therapy Satisfaction Questionnaire (CTSQ) for the FDA
  • Carcinoid protocol review and outcomes strategy in oncology
  • Develop a reimbursement submission checklist in oncology
  • Consulting and participation in an EU/USA payer advisory board meeting on oncology
  • HEOR strategic consulting in oncology
  • Consulting and exploratory analysis of clinical trials of an intravenous drug treatment for cancer
  • Training session on health economics and outcomes research (HEOR) in oncology
  • Advisory board meeting on oncology
  • Strategic consultancy on recommendations of efficacy analyses in oncology using PRO data
  • Symposium oral presentation on clinical trial analyses to support health-related quality of life in oncology
  • Support MRI and qualitative analyses to document conceptual equivalence of an additional linguistic version of the Ascites Impact Measure (AIM) questionnaire
  • Development and validation of a measure of symptomatic malignant ascites leading to paracentesis for relief of abdominal discomfort
  • Assessment of the disease & TX-related symptoms and concepts for 7 oncology indications, and comparison to available measurement tools
  • Development and validation of a generic chemotherapy instrument
  • Psychometric validation of the Cancer Chemotherapy Satisfaction Questionnaire
  • Oncology post trial questionnaire, strategic review and content validation
  • Strategic review and content validation of a measure to evaluate the experience of participating in a clinical trial in oncology
  • Manuscript on the validation of the Cancer Therapy Satisfaction Questionnaire (CTSQ)
  • Literature review on autonomy for an intravenous drug treatment for cancer
  • Preferences and experiences of cancer patients and their families
  • Cognitive debriefing interviews for the development of a generic chemotherapy instrument
  • Team presentation on how to develop a PRO measure and interact with the FDA in oncology
  • Comparison of a generic EQ-5D-3L utility measure to new cancer-specific utility measure (QLU-C10D) and the EQ-5D-3L/5L cross-walks
  • Decision-making survey on granulocyte colony stimulating factor (G-CSF) in oncology
  • Review and confirmation of content validity of an existing cancer quality of life tool
  • Validation and implementation of a cancer tool to asses doctor and patient communication
  • Cognitive debriefing interviews to confirm the face and content validity of the modified cancer care plan communication tools
  • Development of an evidence evaluation framework in cancer
  • Statistical analyses of endpoints in oncology
  • Translations project in oncology

Related categories

Experience,  Oncology,  Therapeutic area